Abbie Celniker

Abbie Celniker

Interim Chief Executive Officer

B.A., Biology - University of California, San Diego
Ph.D., Molecular Biology - University of Arizona

Third Rock Ventures
Novartis AG
Millennium Pharmaceuticals
Wyeth Research

Abbie Celniker is a partner at Third Rock Ventures, and brings 30 years of experience in R&D and senior leadership roles. Abbie focuses on the formation, development and strategy of Third Rock’s portfolio companies. Prior to joining Third Rock Ventures, she served as president and CEO of Eleven Biotherapeutics. Previously, she was the president and CEO of Taligen Therapeutics until the company was acquired by Alexion Pharmaceuticals; following the acquisition, she served as Alexion’s executive vice president, translational medicine. She has served as the global head of biologics of Novartis AG, the senior vice president of R&D strategy and operations of Millennium Pharmaceuticals, and the vice president of protein technologies of the Wyeth Research facilities.

Dr. Celniker is the chair of MassBio’s board of directors, a member of the board of ImaginAb, where she was previously the chair, and a member of the scientific advisory board for Adimab. She currently serves as a board member of Cedilla Therapeutics, Goldfinch Bio and Rheos Medicines. She is also a member of the board of directors of the nonprofit Unitio and T1D.

Dr. Celniker has a B.A. in Biology from the University of California, San Diego, and a Ph.D. in Molecular Biology from the University of Arizona.


This links to an external website.